Full Press Release Details
Tenzing Acquisition Corp. and Reviva
Pharmaceuticals, Inc. Announce Shareholder Meeting Date to
Approve the Business Combination
and Cupertino, Calif., November 18, 2020 - Tenzing Acquisition Corp., a special purpose acquisition company incorporated
in the British Virgin Islands ("Tenzing") (NASDAQ: TZAC), and Reviva Pharmaceuticals, Inc., a Delaware corporation
("Reviva") and a California-based clinical-stage pharmaceutical company developing therapies that address unmet medical
needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that
an Extraordinary General Meeting of Shareholders of Tenzing (the "Shareholder Meeting") to approve the pending business
combination between Tenzing and Reviva (the "Business Combination") is scheduled to be held on Tuesday, December 8,
2020, at 9:00 a.m., Eastern time. Due to COVID-19 restrictions on in-person meetings, the Shareholder Meeting will be completely
virtual and conducted via live webcast.
its definitive proxy statement/prospectus with respect to the Shareholder Meeting related to the Business Combination (the "Proxy
Statement") with the U.S. Securities and Exchange Commission (the "SEC") on November 12, 2020 and began mailing
it to Tenzing shareholders on November 13, 2020. The Proxy Statement is available on the SEC website at www.sec.gov. Holders
of Tenzing's ordinary shares at the close of business on the record date of November 4, 2020 are entitled
to notice of the virtual Shareholder Meeting and to vote at the virtual Shareholder Meeting.
shareholders are asked to read the Proxy Statement, including, among other things, the reasons for Tenzing's Board of Director's
unanimous recommendation that shareholders vote "FOR" the Business Combination and the other proposals set forth in the
Tenzing shareholders
who need assistance in completing the proxy card, require additional copies of the proxy materials, or have questions regarding
the Shareholder Meeting may contact Tenzing's proxy solicitor, Advantage Proxy, Inc., by telephone at (877) 870-8565
(toll free) or by email at ksmith@advantageproxy.com.
About Tenzing Acquisition Corp.
Tenzing is a blank check company formed
for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization
or other similar business combination with one or more businesses or entities. Tenzing's efforts to identify a prospective
target business are not limited to a particular industry or geographic region.
About Reviva Pharmaceuticals, Inc.
Reviva Pharmaceuticals, Inc. is a clinical
stage pharmaceutical company developing therapies that address unmet medical needs in the areas of central nervous system, cardiovascular,
metabolic, and inflammatory diseases. Reviva's primary focus is developing its lead product candidate, RP5063 (brilaroxazine),
for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. Reviva also intends to develop RP5063 for
treating PAH and IPF. RP5063 is a serotonin, dopamine, and nicotinic receptor active compound, which has successfully completed
a global Phase 2 clinical trial and has shown clinical efficacy and safety for schizophrenia and schizoaffective disorder.
Forward-Looking Statements
This press release contains, and certain
oral statements made by representatives of Tenzing and Reviva and their respective affiliates, from time to time may contain, "forward-looking
statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995. Tenzing's and Reviva's actual results may differ from their expectations, estimates and projections and consequently,
you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate,"
"project," "budget," "forecast," "anticipate," "intend," "plan,"
"may," "will," "could," "should," "believes," "predicts,"
"potential," "might" and "continues," and similar expressions are intended to identify such
forward-looking statements. These forward-looking statements include, without limitation, Tenzing's and Reviva's expectations
with respect to future performance and anticipated financial impacts of the Business Combination, the satisfaction of the closing
conditions to the Business Combination and the timing of the completion of the Business Combination. These forward-looking statements
involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of
these factors are outside the control of Tenzing or Reviva and are difficult to predict. Factors that may cause such differences
include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination
of the merger agreement for the Business Combination (the "Merger Agreement"); (2) the inability to complete the Business
Combination, including due to failure to obtain approval of the shareholders of Tenzing or other conditions to closing in the Merger
Agreement; (3) the inability to obtain or maintain the listing of Tenzing's common stock on NASDAQ following the Business
Combination; (4) the risk that the Business Combination disrupts current plans and operations of Reviva as a result of the announcement
and consummation of the Business Combination; (5) the ability to recognize the anticipated benefits of the Business Combination,
which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth economically
and hire and retain key employees; (6) the risks that Reviva's products in development fail clinical trials or are not approved
by the U.S. Food and Drug Administration or other applicable authorities; (7) costs related to the Business Combination; (8) changes
in applicable laws or regulations; (9) the possibility that Tenzing or Reviva may be adversely affected by other economic, business,
and/or competitive factors; and (10) other risks and uncertainties identified in the Proxy Statement, including those under "Risk
Factors" therein, and in other filings with the Securities and Exchange Commission ("SEC") made by Tenzing. The
foregoing list of factors is not exclusive. Readers are cautioned not to place undue reliance upon any forward-looking statements,
which speak only as of the date made. Neither Tenzing nor Reviva undertakes or accepts any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in
events, conditions or circumstances on which any such statement is based, subject to applicable law.
No Offer or Solicitation
This press release is for informational
purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities pursuant to the proposed
Business Combination or otherwise, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation
or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. No offer
of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933,
Important Information about the Business Combination and
In connection with the proposed Business
Combination described herein, Tenzing has filed a registration statement on Form S-4 with the SEC on August 12, 2020, as amended,
which became effective on November 10, 2020 (the "Registration Statement"), and which includes the Proxy Statement.
Tenzing has begun mailing the Proxy Statement and other relevant documents to each shareholder entitled to vote at the Shareholder
Meeting. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND
ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE BUSINESS COMBINATION THAT TENZING HAVE FILED AND WILL FILE WITH THE SEC WHEN
THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT TENZING, REVIVA AND THE BUSINESS COMBINATION. The Registration
Statement and Proxy Statement and other relevant materials in connection with the Business Combination (when they become available),
and any other documents filed by Tenzing with the SEC, may be obtained free of charge at the SEC's website (www.sec.gov)
or by writing to Tenzing Acquisition Corp. at 250 W. 55th St., Suite 13D, New York, NY 10019.
Participants in Solicitation
Tenzing and Reviva and their respective
directors, executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from
the holders of Tenzing ordinary shares in respect of the proposed Business Combination. Information about Tenzing's directors
and executive officers and their ownership of Tenzing's ordinary shares is set forth in Tenzing's Annual Report on
Form 10-K for the year ended February 29, 2020 filed with the SEC, as modified or supplemented by any Form 3 or Form 4 filed with
the SEC since the date of such filing. Other information regarding the interests of the participants in the proxy solicitation
is included in the Registration Statement and Proxy Statement. These documents can be obtained free of charge from the sources
Tenzing Acquisition Corp.
Reviva Pharmaceuticals, Inc.
Laxminarayan Bhat, PhD
Investor Relations Contact:
LifeSci Advisors, LLC